Clinical Trials Logo

Keratosis clinical trials

View clinical trials related to Keratosis.

Filter by:

NCT ID: NCT04693000 Active, not recruiting - Clinical trials for Keratotic Nodular Size

Use of Topical Solasodine of Solanum Melongena Peel Origin in the Treatment of Palmar Arsenic Keratosis

Start date: September 23, 2018
Phase: Phase 2
Study type: Interventional

Arsenic is one of the largest mass poisonings in Bangladesh. Arsenic keratosis of the palm and sole is a common feature of arsenicosis. Brinjal or eggplant ubiquitous vegetable found in different parts of the world, including Bangladesh, scientifically known as Solanum melongena. A study showed ointment containing crude extract of Solanum melongena peel origin is effective in arsenic keratosis. Solasodine is one of the active compounds of Solanum melongena peel. In the current study, an ointment containing a single compound solasodine isolated from Solanum melongena peel . The ointment made from solasodine extract was distributed among arsenic keratosis patients to see the effect.

NCT ID: NCT04688749 Terminated - Melanoma (Skin) Clinical Trials

Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage

DermaSense
Start date: July 17, 2019
Phase:
Study type: Observational

The purpose of this clinical study is to evaluate if the DermaSense prototype EIS scanner can provide medical decision support which can complement dermoscopy-based identification of the disease at time of biopsy decision.

NCT ID: NCT04686474 Recruiting - Clinical trials for Keratotic Nodular Size

Effect of the Compound Extracted From Azadirachta Indica Leaves in the Treatment of Arsenical Keratosis

Start date: October 20, 2019
Phase: N/A
Study type: Interventional

Prepare an ointment from Azadirachta indica leaves extract and its apply on palmer arsenical keratosis patient, for 12 weeks. After intervention, effect of the ointment will be observed by measuring the nodule (before and after apply the ointment)

NCT ID: NCT04686461 Recruiting - Clinical trials for Keratotic Nodular Size

Effect of Thymoquinone Extracted From Nigella Sativa in the Treatment of Arsenical Keratosis

Start date: October 20, 2019
Phase: N/A
Study type: Interventional

Prepare an ointment from Nigella sativa seeds extract and apply it over palmer arsenical keratosis patient for 12 weeks. After than the effect of the ointment will be observed by measuring the keratotic nodular size before and after the intervention.

NCT ID: NCT04642287 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 2026
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

NCT ID: NCT04608461 Recruiting - Clinical trials for Keratotic Nodular Size

Effect of Pumpkin Seeds in the Treatment of Moderate to Severe Palmar Arsenical Keratosis

Start date: September 17, 2019
Phase: Phase 2
Study type: Interventional

Arsenicosis is a major health problem in Bangladesh. Long term exposure of arsenic causes keratosis of palm which reduce working capacity of patient. It also causes massive skin lesions like Bowen's disease which has a risk to develop squamous cell carcinoma. Pumpkin seed is well known for its antioxidant and anticancer properties. So this study will be conducted to identify the compound from pumpkin seeds and to see its outcome on keratosis.

NCT ID: NCT04552327 Completed - Actinic Keratosis Clinical Trials

5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis

KOHDIAK
Start date: October 14, 2020
Phase: Phase 3
Study type: Interventional

The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5% potassium hydroxide solution (Solcera, medical device) versus placebo and investigator-blinded comparison with 3% diclofenac gel (Solaraze, medicinal product). It is performed in accordance with both the laws in force for clinical trials with medical devices and those with medicinal products.

NCT ID: NCT04527653 Completed - Actinic Keratoses Clinical Trials

Evaluation of The Efficacy and Safety of Tixel Treatment for the Treatment of Facial and/or Scalp Actinic Keratoses

Start date: May 14, 2020
Phase: N/A
Study type: Interventional

Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses

NCT ID: NCT04482322 Recruiting - Actinic Keratoses Clinical Trials

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

VDAK
Start date: January 13, 2020
Phase: N/A
Study type: Interventional

This is a prospective clinical trial in which 30 patients will receive a brief (5-day or 14-day) supplementation with 10,000 IU of Vitamin D, prior to receiving aminolevulinic acid (ALA)- blue light PDT for the treatment of actinic keratoses (AKs).

NCT ID: NCT04429308 Not yet recruiting - Actinic Keratoses Clinical Trials

PDT vs Peels for Treatment of Actinic Keratoses

Start date: January 2025
Phase: Phase 2
Study type: Interventional

The purpose of this study is to to compare photodynamic therapy (PDT) versus the combination of Jessner's solution and 35% trichloroacetic acid (TCA) chemical peels for the treatment of actinic keratoses on upper extremities. This is a randomized clinical trial. Approximately 60 participants with actinic keratoses on both upper arms will be randomized to have one arm receive photodynamic therapy, while the contralateral arm receives Jessner's solution followed immediately by 35% TCA. AKs will be counted before treatment and 2-8 weeks after treatment. This study is a pilot study designed to determine the feasibility of this procedure. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.